Is NCT07225816 recruiting in Cypress, CA?

Yes, NCT07225816 is currently recruiting participants at its Cypress, CA location. This obesity clinical trial is actively enrolling qualified participants.

How do I join the obesity clinical trial in Cypress?

To join this clinical trial in Cypress, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Cypress clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Obesity Clinical Trial in Cypress, CA

About This Obesity Study in Cypress

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

Sponsor: Novo Nordisk A/S

Who Can Participate

Inclusion Criteria

\- On maintenance treatment with either liraglutide 3.0 milligram (mg) for at least 5 days, oral semaglutide 25 mg for at least 5 weeks or semaglutide 2.4 mg for at least 5 weeks prior to screening.

Exclusion Criteria

Previous dosing in this study.

Previous rescreening for this study.

Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method

Current participation (i.e., signed informed consent) in any other interventional clinical study.

Exposure to investigational medicinal products, except maintenance treatment with liraglutide 3.0 mg, oral semaglutide 25 mg, or semaglutide 2.4 mg as required by the inclusion criterion, within 30 days or 5 half-lives of the investigational medicinal product (if known), which-ever is longer, before screening (Visit 1).

Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study.

Participant is the investigator or other site staff or relative thereof directly involved in the conduct of the study.

Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the study as judged by the investigator.

Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.

History of major surgical procedures involving the oesophagus or stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant a\*.

Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per min per 1.73 square meter (ml/min/1.73 m\^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation according to Kidney Disease Improving Global Outcomes (KDIGO) 20246.

Current treatment with insulin or secretagogues that might cause hypoglycaemia during periods of fasting.

History of ketoacidosis.

Diagnosed with or suspected to suffer from clinically significant gastroparesis, hiatal hernia or severe gastroesophageal reflux diseases with daily symptoms and/or in supine position.

Use of other medications known to affect the motility of the stomach.

Inability to lie in the right lateral decubitus position for gastric ultrasonography.

Unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study.

As declared by the participant or reported in the medical records.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cypress?

Yes, this clinical trial (NCT07225816) has an active research site in Cypress, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obesity Treatment Options in Cypress, CA

If you're searching for obesity treatment options in Cypress, CA, this clinical trial (NCT07225816) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cypress research site is actively enrolling participants for this clinical trial. You'll receive care from experienced obesity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obesity clinical trials near you to find additional studies recruiting in your area.

Obesity Clinical Trial in Cypress, CA

Expert Care in Cypress

IRB Approved

No-Cost Care

Apply for This Cypress Location

Why Participate?

Simple Process